查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813234

2032 年人工智慧腫瘤映射市場預測：按癌症類型、技術、應用、最終用戶和地區進行的全球分析

AI Tumor Evolution Maps Market Forecasts to 2032 - Global Analysis By Cancer Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球 AI 腫瘤映射市場預計在 2025 年達到 1.9603 億美元，到 2032 年將達到 13.9077 億美元，預測期內的複合年成長率為 32.3%。

人工智慧腫瘤進展圖譜是一套創新系統，旨在研究癌症如何隨時間推移發展、變異以及對不同治療的反應。這些圖譜處理廣泛的基因組圖譜、醫學掃描和患者記錄，以揭示腫瘤進展的動態特性。透過揭示癌細胞如何適應和獲得抗藥性，它們可以幫助研究人員預測臨床結果並制定個人化治療方案。與傳統方法不同，人工智慧主導的模型整合了多種資料集，揭示了腫瘤生物學中原本可能隱藏的微妙相互作用。這種前沿方法為腫瘤學家提供了更深入的洞察，使他們能夠做出更精準的治療決策，並改善癌症管理的前景。

根據國際癌症研究機構（IARC）的數據，預計癌症相關死亡人數將從 2008 年的 760 萬人增加到 2030 年的 1,300 萬人。

癌症發生率增加

全球癌症患者數量的成長極大地推動了對人工智慧腫瘤進展圖譜的需求。隨著越來越多的患者確診，醫療保健系統需要先進的工具來追蹤腫瘤生長、預測變化並支持個人化治療決策。基於人工智慧的圖譜使臨床醫生能夠處理大量的基因組和臨床資料集，從而增強護理管理。人們對癌症風險和治療方案的認知不斷提高，以及癌症類型的不斷增加，進一步刺激了這些技術的普及。這種情況正在推動對支持早期發現、制定針對性治療策略和提高患者存活率的人工智慧解決方案的投資，使其成為現代腫瘤學實踐中不可或缺的一部分。

實施成本高

實施人工智慧腫瘤映射的高昂成本是市場發展的一大限制因素。建置和維護此類系統需要在計算硬體、軟體解決方案和熟練的專業人員方面投入巨額資金。規模較小的醫療機構通常無法負擔這些成本，從而限制了其使用人工智慧腫瘤映射技術。軟體更新、資料管理以及與現有臨床工作流程整合相關的額外費用進一步加劇了這項挑戰。這些經濟障礙可能會減緩市場成長，限制新競爭對手的進入，並阻礙其在新興市場的普及。儘管人工智慧腫瘤映射工具具有諸多優勢，但高昂的實施成本仍是阻礙其在全球醫院和診所廣泛應用的重要因素。

精準腫瘤學需求不斷成長

精準腫瘤學日益成長的興趣為AI腫瘤映射市場提供了巨大的成長潛力。患者和醫療保健提供者都越來越尋求個人化治療方法，這些方法可以考慮個別腫瘤特徵、基因變異和治療結果。基於AI的腫瘤映射平台可以分析複雜訊息，檢測細微模式，並為客製化治療產生可行的建議。隨著精準醫療的普及，對支持精準預後、最佳化治療和預測抗藥性的AI工具的需求日益成長。透過利用這一需求，基於AI的腫瘤映射解決方案提供者可以擴大其市場範圍，改善患者照護，並在全球範圍內推進靶向癌症治療的實施。

與傳統方法的競爭

傳統的癌症診斷和監測技術對AI腫瘤進展圖譜市場構成了威脅。傳統方法，例如切片檢查、病理學檢查和標準成像技術，已經成熟、可靠，並且通常比AI主導的平台更實惠。醫療保健提供者可能會因為對準確性、工作流程整合和培訓要求的擔憂而猶豫是否採用新的AI技術。這種不願意採用新方法的態度可能會減緩AI腫瘤進展解決方案的市場滲透速度，尤其是在資源有限的地區。傳統方法也受益於監管部門的核准經驗和廣泛的臨床檢驗。因此，AI平檯面臨著來自傳統方法的激烈競爭，儘管存在潛在的技術改進，但這可能會限制它們的採用。

COVID-19的影響：

COVID-19疫情對AI腫瘤映射市場產生了顯著影響。許多醫院和研究中心的常規癌症護理（包括篩檢、監測和臨床研究）中斷，暫時減少了對基於AI的腫瘤映射系統的需求。供應鏈延遲進一步阻礙了必要硬體和軟體的部署。相反，疫情加速了數位健康解決方案、遠端醫療和AI分析的整合，彰顯了遠端監控和預測性醫療工具的關鍵作用。雖然短期市場成長因此放緩，但COVID-19疫情凸顯了AI腫瘤映射平台在改善病患管理、增強決策能力和增強醫療韌性方面的重要性。

預計乳癌將成為預測期內最大的癌症類別

預計乳癌領域將在預測期內佔據最大的市場佔有率。這種主導地位源於全球乳癌的高發病率以及旨在改善乳癌治療的人工智慧研究的大量投資。包括深度學習模型和先進影像技術在內的人工智慧驅動工具顯著改善了乳癌患者早期檢測、個人化治療策略以及腫瘤發展的持續監測。隨著人工智慧技術的不斷發展，其在乳癌的應用預計將不斷擴展，從而鞏固其在人工智慧腫瘤映射市場中的主導地位。

預計人工智慧和健康科技新興企業領域在預測期內的複合年成長率最高

預計人工智慧與健康科技新興企業領域將在預測期內實現最高成長率。這一成長將由個人化醫療領域的創新推動，人工智慧可根據個人的基因資訊、生活方式和健康史量身定做治療方案。此外，這些新興企業正在率先將人工智慧與基因組學和臨床數據相結合，提供創新的解決方案，顯著提高癌症診斷和治療策略的準確性和有效性。他們的適應能力和對尖端技術的專注，使其成為快速推進人工智慧腫瘤學領域的關鍵參與者。

比最大的地區

預計北美將在預測期內佔據最大的市場佔有率。其領先地位得益於先進的醫療設施、巨額的研發投入以及較高的癌症發生率等因素。包括優惠法規和舉措創造了一個強大的生態系統。

複合年成長率最高的地區：

預計亞太地區在預測期內的複合年成長率最高。這一快速成長得益於癌症患病率上升、醫療基礎設施改善以及人工智慧在醫療診斷中的應用日益廣泛等因素。中國、日本和印度等國家正大力投資人工智慧研發，為市場成長創造了有利環境。此外，醫療機構與科技公司之間的夥伴關係也促進了人工智慧解決方案在腫瘤學領域的整​​合。這些因素共同作用，使亞太地區成為全球人工智慧腫瘤映射市場的主要參與者。

提供免費客製化

訂閱此報告的用戶將獲得以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章全球人工智慧腫瘤映射市場（按癌症類型）

  • 腦腫瘤
  • 肺癌
  • 乳癌
  • 大腸直腸癌
  • 攝護腺癌
  • 胰臟癌
  • 造血系統惡性腫瘤
  • 罕見癌症和兒童癌症
  • 其他癌症類型

6. 全球人工智慧腫瘤映射市場（按技術）

  • 基於影像的映射（MRI、CT、PET）
  • 基因組和轉錄組圖譜
  • 人工智慧預測模型
  • 多組體學整合平台
  • 空間轉錄組學
  • 數位雙胞胎建模
  • 聯邦學習和隱私保護人工智慧

7. 全球人工智慧腫瘤映射市場（按應用）

  • 診斷和早期檢測
  • 預後和風險評估
  • 治療計劃
  • 藥物開發和臨床試驗
  • 腫瘤監測和復發預測
  • 生物標記發現
  • 免疫治療中的患者分層

8. 全球人工智慧腫瘤映射市場（按最終用戶）

  • 醫院和診所
  • 研究所
  • 製藥和生物技術公司
  • 學術機構
  • 診斷實驗室
  • 人工智慧和健康科技Start-Ups

9. 全球人工智慧腫瘤映射市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Azra AI
  • Siemens Healthineers AG
  • GE HealthCare
  • NVIDIA Corporation
  • Median Technologies
  • PathAI
  • Paige
  • AstraZeneca
  • CancerIQ
  • X-ZELL
  • MNM Bioscience
  • Biotome
  • Immunai
  • OncoHost
  • Tempus
  • 1Cell.Ai
Product Code: SMRC30693

According to Stratistics MRC, the Global AI Tumor Evolution Maps Market is accounted for $196.03 million in 2025 and is expected to reach $1390.77 million by 2032 growing at a CAGR of 32.3% during the forecast period. Artificial Intelligence Tumor Evolution Maps are innovative systems designed to study how cancers develop, mutate, and react to different therapies over time. These maps process extensive genomic profiles, medical scans, and patient records to uncover the dynamic nature of tumor progression. By revealing how cancer cells adapt and acquire drug resistance, they assist researchers in forecasting clinical outcomes and tailoring personalized treatments. Unlike conventional approaches, AI-driven models merge diverse datasets, highlighting subtle interactions within tumor biology that might otherwise remain hidden. This cutting-edge methodology equips oncologists with deeper insights, enabling more accurate therapeutic decisions and offering improved prospects for cancer management.

According to the International Agency for Research on Cancer (IARC), The number of cancer-associated deaths is projected to increase from 7.6 million in 2008 to 13 million in 2030-a rise of approximately 72%.

Market Dynamics:

Driver:

Increasing cancer incidence

The global rise in cancer cases is significantly boosting the demand for AI Tumor Evolution Maps. With more patients being diagnosed, healthcare systems require sophisticated tools to track tumor growth, anticipate changes, and support individualized therapy decisions. AI-based maps allow clinicians to process extensive genomic and clinical datasets, enhancing care management. Increasing awareness of cancer risks and treatment options, along with the growth of various cancer types, further stimulates the adoption of these technologies. This situation drives investment in AI solutions that aid in early detection, precise treatment strategies, and improved patient survival, making them an essential part of modern oncology practices.

Restraint:

High implementation costs

The significant cost of implementing AI Tumor Evolution Maps is a major market restraint. Establishing and maintaining these systems requires heavy investment in computing hardware, software solutions, and skilled professionals. Smaller healthcare facilities often cannot bear these costs, limiting their access to AI-powered tumor mapping. Additional expenses related to software updates, data management, and integration with existing clinical workflows further compound the challenge. These financial barriers can slow market growth, restrict the entry of new competitors, and hinder adoption in developing regions. Despite the advantages of AI-driven tumor evolution tools, high implementation costs remain a critical factor preventing broader utilization across hospitals and clinics worldwide.

Opportunity:

Increasing demand for precision oncology

Rising interest in precision oncology offers strong growth potential for the AI Tumor Evolution Maps market. Both patients and healthcare providers are increasingly focused on personalized treatment approaches that consider individual tumor characteristics, genetic alterations, and therapy outcomes. AI-enabled tumor evolution platforms can analyze complex information, detect subtle patterns, and generate actionable recommendations for customized treatments. As precision medicine gains traction, the need for AI tools that support accurate prognosis, optimize therapy, and anticipate resistance is growing. Providers of AI-based tumor mapping solutions can capitalize on this demand to expand their market reach, improve patient care, and advance the implementation of targeted cancer therapies globally.

Threat:

Competition from traditional methods

Traditional cancer diagnostic and monitoring techniques present a threat to the AI Tumor Evolution Maps market. Traditional approaches such as biopsies, pathology examinations, and standard imaging techniques are well-established, reliable, and generally more affordable compared to AI-driven platforms. Healthcare providers may hesitate to implement new AI technologies due to concerns over accuracy, workflow integration, and training requirements. Resistance to adopting novel approaches can slow the market penetration of AI tumor evolution solutions, especially in resource-limited regions. Traditional methods also benefit from regulatory approval experience and extensive clinical validation. As a result, AI platforms face strong competition from conventional practices, which may limit adoption despite the potential for technological improvements.

Covid-19 Impact:

The COVID-19 pandemic had a notable effect on the AI Tumor Evolution Maps market. Many hospitals and research centers experienced disruptions in routine cancer care, including screenings, therapies, and clinical studies, leading to a temporary decline in demand for AI-based tumor mapping systems. Supply chain delays further hindered the deployment of necessary hardware and software. Conversely, the pandemic accelerated the integration of digital health solutions, telemedicine, and AI analytics, demonstrating the critical role of remote monitoring and predictive healthcare tools. Consequently, although short-term market growth slowed, COVID-19 underscored the importance of AI tumor evolution platforms in improving patient management, enhancing decision-making, and strengthening healthcare resilience.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is expected to account for the largest market share during the forecast period. This dominance is due to the high prevalence of breast cancer worldwide and significant investments in AI research aimed at improving breast cancer care. AI-driven tools, including deep learning models and sophisticated imaging technologies, have significantly improved early detection, tailored treatment strategies, and ongoing monitoring of tumor development in breast cancer patients. As AI technologies continue to evolve, their application in breast cancer is expected to expand, reinforcing its leading role in the AI tumor mapping market.

The AI & health tech startups segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the AI & health tech startups segment is predicted to witness the highest growth rate. This growth is fueled by innovations in personalized medicine, where AI customizes treatments based on individual genetic information, lifestyle, and health history. Moreover, these startups are pioneering the integration of AI with genomics and clinical data, providing novel solutions that significantly improve the precision and effectiveness of cancer diagnostics and treatment strategies. Their adaptability and emphasis on advanced technologies establish them as key players in the rapidly advancing field of AI-powered oncology.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by factors such as cutting-edge healthcare facilities, significant R&D investments, and a high incidence of cancer. Government support, including favorable regulations and initiatives, has further accelerated the adoption of AI technologies in oncology. The concentration of prominent technology firms and prestigious medical institutions in the region has created a robust ecosystem for the advancement and implementation of AI-based cancer diagnostic and treatment solutions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. This surge is attributed to factors such as a rising prevalence of cancer, improvements in healthcare infrastructure, and an increased adoption of artificial intelligence in medical diagnostics. Nations like China, Japan, and India are making substantial investments in AI research and development, creating a favorable environment for market growth. Furthermore, partnerships between healthcare institutions and technology companies are facilitating the integration of AI solutions in oncology. These factors collectively position the APAC region as a key player in the global AI Tumor Evolution Maps market.

Key players in the market

Some of the key players in AI Tumor Evolution Maps Market include Azra AI, Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Median Technologies, PathAI, Paige, AstraZeneca, CancerIQ, X-ZELL, MNM Bioscience, Biotome, Immunai, OncoHost, Tempus and 1Cell.Ai.

Key Developments:

In August 2025, GE HealthCare and Gentuity LLC plan to collaborate on commercial activities to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology. The collaboration is intended to enhance the availability, adoption and functionality of highly complementary imaging solutions for interventional cardiology.

In April 2025, Azra AI and Elekta announce partnership to enhance cancer registry operations with AI-powered automation. This partnership combines Azra AI's real-time patient identification and workflow automation with Elekta's next-generation cancer registry software, Elekta ONE Registry Informatics*. The combined technologies will enable cancer registry teams to automate cancer casefinding, streamline data ingestion, increase reporting accuracy, and ensure compliance with national and international standards.

In January 2025, Siemens Healthineers has entered into a technology licensing agreement with Kromek Group Plc to enable the in-house production of cadmium zinc telluride (CZT) material for gamma ray detectors used in single-photon emission computed tomography (SPECT) systems. Under the terms of the agreement, Siemens Healthineers will license Kromek's technology to produce CZT, which will extend its research, development, and manufacturing capabilities to allow for a potential future line of gamma ray detectors for multi-modal SPECT systems.

Cancer Types Covered:

  • Brain Cancer
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Hematologic Malignancies
  • Rare & Pediatric Cancers
  • Other Cancer Types

Technologies Covered:

  • Imaging-Based Mapping (MRI, CT, PET)
  • Genomic and Transcriptomic Mapping
  • AI-Powered Predictive Modeling
  • Multi-Omics Integration Platforms
  • Spatial Transcriptomics
  • Digital Twin Modeling
  • Federated Learning & Privacy-Preserving AI

Applications Covered:

  • Diagnosis and Early Detection
  • Prognosis and Risk Assessment
  • Treatment Planning
  • Drug Development and Clinical Trials
  • Tumor Monitoring and Recurrence Prediction
  • Biomarker Discovery
  • Patient Stratification for Immunotherapy

End Users Covered:

  • Hospitals and Clinics
  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Academic Institutions
  • Diagnostic Laboratories
  • AI & Health Tech Startups

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global AI Tumor Evolution Maps Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Brain Cancer
  • 5.3 Lung Cancer
  • 5.4 Breast Cancer
  • 5.5 Colorectal Cancer
  • 5.6 Prostate Cancer
  • 5.7 Pancreatic Cancer
  • 5.8 Hematologic Malignancies
  • 5.9 Rare & Pediatric Cancers
  • 5.10 Other Cancer Types

6 Global AI Tumor Evolution Maps Market, By Technology

  • 6.1 Introduction
  • 6.2 Imaging-Based Mapping (MRI, CT, PET)
  • 6.3 Genomic and Transcriptomic Mapping
  • 6.4 AI-Powered Predictive Modeling
  • 6.5 Multi-Omics Integration Platforms
  • 6.6 Spatial Transcriptomics
  • 6.7 Digital Twin Modeling
  • 6.8 Federated Learning & Privacy-Preserving AI

7 Global AI Tumor Evolution Maps Market, By Application

  • 7.1 Introduction
  • 7.2 Diagnosis and Early Detection
  • 7.3 Prognosis and Risk Assessment
  • 7.4 Treatment Planning
  • 7.5 Drug Development and Clinical Trials
  • 7.6 Tumor Monitoring and Recurrence Prediction
  • 7.7 Biomarker Discovery
  • 7.8 Patient Stratification for Immunotherapy

8 Global AI Tumor Evolution Maps Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Clinics
  • 8.3 Research Institutes
  • 8.4 Pharmaceutical & Biotechnology Companies
  • 8.5 Academic Institutions
  • 8.6 Diagnostic Laboratories
  • 8.7 AI & Health Tech Startups

9 Global AI Tumor Evolution Maps Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Azra AI
  • 11.2 Siemens Healthineers AG
  • 11.3 GE HealthCare
  • 11.4 NVIDIA Corporation
  • 11.5 Median Technologies
  • 11.6 PathAI
  • 11.7 Paige
  • 11.8 AstraZeneca
  • 11.9 CancerIQ
  • 11.10 X-ZELL
  • 11.11 MNM Bioscience
  • 11.12 Biotome
  • 11.13 Immunai
  • 11.14 OncoHost
  • 11.15 Tempus
  • 11.16 1Cell.Ai

List of Tables

  • Table 1 Global AI Tumor Evolution Maps Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global AI Tumor Evolution Maps Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 3 Global AI Tumor Evolution Maps Market Outlook, By Brain Cancer (2024-2032) ($MN)
  • Table 4 Global AI Tumor Evolution Maps Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 5 Global AI Tumor Evolution Maps Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 6 Global AI Tumor Evolution Maps Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 7 Global AI Tumor Evolution Maps Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 8 Global AI Tumor Evolution Maps Market Outlook, By Pancreatic Cancer (2024-2032) ($MN)
  • Table 9 Global AI Tumor Evolution Maps Market Outlook, By Hematologic Malignancies (2024-2032) ($MN)
  • Table 10 Global AI Tumor Evolution Maps Market Outlook, By Rare & Pediatric Cancers (2024-2032) ($MN)
  • Table 11 Global AI Tumor Evolution Maps Market Outlook, By Other Cancer Types (2024-2032) ($MN)
  • Table 12 Global AI Tumor Evolution Maps Market Outlook, By Technology (2024-2032) ($MN)
  • Table 13 Global AI Tumor Evolution Maps Market Outlook, By Imaging-Based Mapping (MRI, CT, PET) (2024-2032) ($MN)
  • Table 14 Global AI Tumor Evolution Maps Market Outlook, By Genomic and Transcriptomic Mapping (2024-2032) ($MN)
  • Table 15 Global AI Tumor Evolution Maps Market Outlook, By AI-Powered Predictive Modeling (2024-2032) ($MN)
  • Table 16 Global AI Tumor Evolution Maps Market Outlook, By Multi-Omics Integration Platforms (2024-2032) ($MN)
  • Table 17 Global AI Tumor Evolution Maps Market Outlook, By Spatial Transcriptomics (2024-2032) ($MN)
  • Table 18 Global AI Tumor Evolution Maps Market Outlook, By Digital Twin Modeling (2024-2032) ($MN)
  • Table 19 Global AI Tumor Evolution Maps Market Outlook, By Federated Learning & Privacy-Preserving AI (2024-2032) ($MN)
  • Table 20 Global AI Tumor Evolution Maps Market Outlook, By Application (2024-2032) ($MN)
  • Table 21 Global AI Tumor Evolution Maps Market Outlook, By Diagnosis and Early Detection (2024-2032) ($MN)
  • Table 22 Global AI Tumor Evolution Maps Market Outlook, By Prognosis and Risk Assessment (2024-2032) ($MN)
  • Table 23 Global AI Tumor Evolution Maps Market Outlook, By Treatment Planning (2024-2032) ($MN)
  • Table 24 Global AI Tumor Evolution Maps Market Outlook, By Drug Development and Clinical Trials (2024-2032) ($MN)
  • Table 25 Global AI Tumor Evolution Maps Market Outlook, By Tumor Monitoring and Recurrence Prediction (2024-2032) ($MN)
  • Table 26 Global AI Tumor Evolution Maps Market Outlook, By Biomarker Discovery (2024-2032) ($MN)
  • Table 27 Global AI Tumor Evolution Maps Market Outlook, By Patient Stratification for Immunotherapy (2024-2032) ($MN)
  • Table 28 Global AI Tumor Evolution Maps Market Outlook, By End User (2024-2032) ($MN)
  • Table 29 Global AI Tumor Evolution Maps Market Outlook, By Hospitals and Clinics (2024-2032) ($MN)
  • Table 30 Global AI Tumor Evolution Maps Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 31 Global AI Tumor Evolution Maps Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 32 Global AI Tumor Evolution Maps Market Outlook, By Academic Institutions (2024-2032) ($MN)
  • Table 33 Global AI Tumor Evolution Maps Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global AI Tumor Evolution Maps Market Outlook, By AI & Health Tech Startups (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.